Dermata Therapeutics, Inc. reported financial results for year ended December 31, 2025.
“Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025”
Dermata Therapeutics, Inc. — fact timeline
Source-grounded facts extracted from Dermata Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Dermata Therapeutics, Inc. engaged CBIZ CPAs P.C. as its auditor.
“On February 2, 2026, the Audit Committee approved the appointment of CBIZ CPAs P.C., (formerly known as Mayer Hoffman McCann P.C.) (“CBIZ CPAs”) as the Company’s new independent registered public accounting firm.”
Dermata Therapeutics, Inc. dismissed Baker Tilly US, LLP as its auditor.
“On January 30, 2026, Dermata Therapeutics, Inc. (the “Company”) notified Baker Tilly US, LLP (formerly Moss Adams LLP) (“Baker Tilly”) that Baker Tilly would be dismissed as the Company’s independent registered public accounting firm.”
Dermata Therapeutics, Inc. amended Warrant Amendment Agreements with certain holders of the Company’s outstanding warrants that participated as investors in the Private Placement (effective 2025-12-23).
“Pursuant to warrant amendment agreements each dated December 23, 2025, among the Company and certain holders of the Company’s outstanding warrants that participated as investors in the Private Placement (collectively, the “ Warrant Amendment Agreements ”), the Company amended certain outstanding warrants to purchase up to an aggregate of 120,734 share”
Dermata Therapeutics, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC valued at 7.0% of the aggregate gross proceeds of the Private Placement raised from outside institutional and.
“Pursuant to the Engagement Letter, the Company paid Wainwright (i) a cash fee equal to (x) 7.0% of the aggregate gross proceeds of the Private Placement raised from outside institutional and accredited investors, and (y) 3.5% of the aggregate gross proceeds of the Private Placement raised from insider investors, (iii) a management fee of 1.0% of the aggregate gross proceeds of the Private Placement, (iv) a non-accountable expense allowance of $25,000, and (v) an out-of-pocket expense allowance of $40,000.”
Dermata Therapeutics, Inc. entered into Registration Rights Agreement with the investors (effective 2025-12-23).
“In connection with the Private Placement, the Company entered into a registration rights agreement (the “ Registration Rights Agreement ”), dated as of December 23, 2025, with the investors, pursuant to which the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission (the “ SEC ”) registering the resale of the Shares and the shares of Common Stock underlying the Pre-Funded Warrants and the Warrants no later than thirty (30) days after the date of the Registration Rights Agreement (the “ Registration Statement ”), and to use its best efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than sixty (60) days following the date of the Registration Rights Agreement (or ninety (90) days following the date of the Registration Rights Agreement in the event of a “full review” by the SEC).”
Dermata Therapeutics, Inc. entered into Purchase Agreement with certain institutional and accredited investors valued at purchase price per Share and accompanying Warrants was $2.04 (effective 2025-12-23).
“On December 23, 2025, Dermata Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain institutional and accredited investors for the issuance and sale in a private placement (the “ Private Placement ”) of (i) 1,484,312 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), (ii) pre-funded warrants (“ Pre-Funded Warrants ”) to purchase up to 537,750 shares of Common Stock, at an exercise price of $0.001 per share, (iii) series C warrants (the “ Series C Warrants ”) to purchase up to 2,022,062 shares of Common Stock, and (iv) series D warrants (the “ Series D Warrants ” together with the Series C Warrants, the “ Warrants ”) to purchase up to 2,022,062 shares of Common Stock.”
Dermata Therapeutics, Inc.: Certificate of Amendment filed to effect a one-for-10 reverse stock split of common stock (effective 2025-08-01).
“On July 30, 2025, Dermata Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which will effect, at 12:01 a.m. Eastern Time, on August 1, 2025, a one-for-10 (1:10) reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).”
Dermata Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“July 2, 2025, the Panel notified the Company that it has granted Company’s request for an exception until August 14, 2025, to demonstrate compliance with the Minimum Bid Price Requirement (the “Exception”). Pursuant to the Exception, the Company is required to provide the Panel with prompt notification of any significant events that occur, including any event that may call into question the Company’s ability to satisfy the terms of the Exception. The Company is actively pursuing measures to regain compliance with the Minimum Bid Price Requirement, including seeking shareholder approval for a r”
Dermata Therapeutics, Inc. engaged Baker Tilly US, LLP as its auditor.
“In connection with the notification of the merger, the audit committee of the Company’s Board of Directors approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company’s independent registered public accounting firm.”
Dermata Therapeutics, Inc. entered into Inducement Letter with holders of Existing Warrants valued at aggregate gross proceeds of approximately $2.66 million (effective 2024-05-17).
“On May 17, 2024, Dermata Therapeutics, Inc. (the “ Company ”) entered into inducement offer letter agreements (each, an “ Inducement Letter ”) with holders (the “ Holders ”) of certain of the Company's existing warrants”
Dermata Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“May 14, 2024, the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to November 11, 2024, to regain compliance with the Minimum Bid Price Requirement. As previously disclosed on May 14, 2024, in order to regain compliance with the Minimum Bid Price Requirement, the Company has filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware which will effect, at 12:01 a.m. Eastern Time, on May 16, 2024, a one-for-fifteen (1:15) reverse stock split of the Co”
Dermata Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $3.1 million of net loss.
“The decrease in cash and cash equivalents resulted from $3.1 million of net loss for the quarter ended March 31, 2024, and $0.2 million of decreased accrued liabilities, offset by $0.6 million in stock-based compensation expense.”
Dermata Therapeutics, Inc.: Effected a one-for-fifteen reverse stock split by filing a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (effective 2024-05-16).
“On May 14, 2024, Dermata Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which will effect, at 12:01 a.m. Eastern Time, on May 16, 2024, a one-for-fifteen (1:15) reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).”
Dermata Therapeutics, Inc. shareholders approved Election of three Class III directors.
“The matters voted on at the Annual Meeting were: (1) the election of three Class III directors”
Dermata Therapeutics, Inc. reported financial results for full year ended December 31, 2023.
“On March 21, 2024, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.